Bispecific Antibodies
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global bispecific antibody market trends, R&D, clinical trials, and regulatory approvals for strategic pharma investment and BD.
Showing 1–4 of 4 articles
Quick answer
NovaPharmaNews Bispecific Antibodies hub for FDA covers 4 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Aclaris Therapeutics ATI-052 Shows Promising 45-Day Half-Life in Phase 1a Trial Results
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Akeso's Cadonilimab Shows Promising Survival Benefit in Advanced Pancreatic Cancer Phase II Trial
EpiBiologics Begins Phase 1 Trial of EPI-326 Bispecific Antibody for EGFR-Driven Cancers
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.